Beijing Beilu Pharmaceutical (300016.SZ): In the first half of the year, all of the company's comparative agents successfully entered the international market and achieved significant revenue growth.

Gelonghui Finance · Sep 12 16:11

Gelonghui September 12 | Hokuriku Pharmaceutical (300016.SZ) was surveyed by a specific target on September 11, 2024. Regarding “the company's expansion in overseas markets,” the company said that after solid groundwork and unremitting exploration in previous years, the results of the company's overseas market expansion efforts were outstanding. In the first half of 2024, the company successfully launched its entire line of contrast products and achieved a significant increase in revenue. In terms of APIs, not only does Haichang Pharmaceutical continue to expand overseas markets for its iodine APIs, but the Cangzhou branch has also gradually internationalized the production of gadolinium APIs. With the completion of EU EDQMGMP certification and Brazilian compliance certification, the internationalization of the company's contrast products is expected to accelerate further. The registration of Jiuwei Zhenxin granules in Hong Kong and Thailand continues to proceed according to plan, creating conditions for export to Southeast Asia and other places.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

北陆药业(300016.SZ)：上半年对比剂全线产品成功出海并实现营收大幅增长

Beijing Beilu Pharmaceutical (300016.SZ): In the first half of the year, all of the company's comparative agents successfully entered the international market and achieved significant revenue growth.

Risk Disclaimer

Statement